Stockreport

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update [Yahoo! Finance]

aTyr Pharma, Inc.  (ATYR) 
PDF Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study reinforces its favorable safety profile. Publication in Science Translational Medicine validate [Read more]